These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15876849)

  • 1. Calcium, phosphorus and vitamin D disorders in uremia.
    Slatopolsky E; Brown A; Dusso A
    Contrib Nephrol; 2005; 149():261-271. PubMed ID: 15876849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium and phosphorus metabolism in chronic uremia.
    Fiaschi E; Mioni G; Maschio G; D'Angelo A; Ossi E
    Nephron; 1975; 14(2):163-80. PubMed ID: 1093055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.
    Cozzolino M; Lu Y; Finch J; Slatopolsky E; Dusso AS
    Kidney Int; 2001 Dec; 60(6):2109-17. PubMed ID: 11737585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure.
    Denda M; Finch J; Slatopolsky E
    Am J Kidney Dis; 1996 Oct; 28(4):596-602. PubMed ID: 8840952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E; Brown A; Dusso A
    Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S54-7. PubMed ID: 11158862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate.
    Canalejo A; Canalejo R; Rodriguez ME; Martinez-Moreno JM; Felsenfeld AJ; Rodríguez M; Almaden Y
    Nephrol Dial Transplant; 2010 Apr; 25(4):1087-97. PubMed ID: 19934096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth.
    Dusso AS; Pavlopoulos T; Naumovich L; Lu Y; Finch J; Brown AJ; Morrissey J; Slatopolsky E
    Kidney Int; 2001 Mar; 59(3):855-65. PubMed ID: 11231340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E; Brown A; Dusso A
    Kidney Int Suppl; 1999 Dec; 73():S14-9. PubMed ID: 10633458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate.
    Brown AJ; Ritter CS; Finch JL; Slatopolsky EA
    Kidney Int; 1999 Apr; 55(4):1284-92. PubMed ID: 10200992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid growth and suppression in renal failure.
    Lewin E; Huan J; Olgaard K
    Semin Dial; 2006; 19(3):238-45. PubMed ID: 16689976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
    Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
    J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involution of the parathyroid glands after renal transplantation.
    Lewin E
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):363-71. PubMed ID: 12815332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure.
    Slatopolsky E; Dusso A; Brown AJ
    Am J Med Sci; 1999 Jun; 317(6):370-6. PubMed ID: 10372836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
    Slatopolsky E; Cozzolino M; Lu Y; Finch J; Dusso A; Staniforth M; Wein Y; Webster J
    Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E; Delmez JA
    Nephrol Dial Transplant; 1996; 11 Suppl 3():130-5. PubMed ID: 8840328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.
    Slatopolsky E; Finch J; Denda M; Ritter C; Zhong M; Dusso A; MacDonald PN; Brown AJ
    J Clin Invest; 1996 Jun; 97(11):2534-40. PubMed ID: 8647946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of secondary hyperparathyroidism by cimetidine in chronically uremic dogs.
    Jacob AI; Canterbury JM; Gavellas G; Lambert PW; Bourgoignie JJ
    J Clin Invest; 1981 Jun; 67(6):1753-60. PubMed ID: 7240419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia.
    Arcidiacono MV; Cozzolino M; Brancaccio D; Gallieni M; Lesma E; Carelli S; Gorio A; Di Giulio AM
    J Nephrol; 2007; 20(2):228-33. PubMed ID: 17514628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of parathyroid hyperplasia in renal failure.
    Cozzolino M; Brancaccio D; Gallieni M; Galassi A; Slatopolsky E; Dusso A
    J Nephrol; 2005; 18(1):5-8. PubMed ID: 15772917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.